ENTERA BIO LTD (ENTX) Stock News
NASDAQ:ENTX - Nasdaq - IL0011429839 - Common Stock - Currency: USD
ENTX Latest News, Press Relases and Analysis
Entera Bio to Participate in Upcoming Events
JERUSALEM, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of oral peptide and...
EFFECTS OF EB613 TABLETS [ORAL PTH(1-34)] ON TRABECULAR AND CORTICAL BONE USING 3D-DXA: POST-HOC RESULTS FROM PHASE 2 STUDY Accepted for Oral Presentation at World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases
JERUSALEM , Feb. 19, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of oral peptide and...
Entera Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
JERUSALEM, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered...
Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates
JERUSALEM, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of oral peptides and...
Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders
JERUSALEM and MIAMI, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (Entera), a leader in the development of orally delivered...
ENTX Stock Earnings: Entera Bio Meets EPS for Q2 2024
ENTX stock results show that Entera Bio met analyst estimates for earnings per share the second quarter of 2024.
ENTX Stock Earnings: Entera Bio Beats EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Entera Bio (NASDAQ:ENTX) just reported results for the first quarter of 2024.En...
ENTX Stock Earnings: Entera Bio Beats EPS for Q1 2024
ENTX stock results show that Entera Bio beat analyst estimates for earnings per share the first quarter of 2024.
Entera Bio to Participate in Upcoming Investor and Scientific Conferences
JERUSALEM, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered...
Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates
JERUSALEM , Aug. 09, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered...
3 Meme Stocks to Buy and Hold for Potential 300% Returns in 3 Years
These are the meme stocks to buy as they represent fundamentally strong ideas with major growth acceleration catalysts.
3 Meme Stocks That Can Surge by 200% Before 2025
Don't wait too long on these attractive meme stocks to buy for 200% upside, as they represent good businesses with growth catalysts.
3 Clinical-Stage Biotech Stocks to Buy for Multibagger Returns
These are the clinical-stage biotech stocks to buy, as they represent companies with an attractive product pipeline.
3 Meme Stocks to Buy on the Dip: June 2024
Investors can't miss out on meme stocks to buy on the dip since these represent fundamentally sound ideas with growth acceleration catalysts
7 Penny Stocks to Turn $3 Into $1 Million Within 36 Months
Wise investors consider penny stocks to buy which represent companies with vigorous fundamentals and a robust growth outlook.
Rag to Riches: 3 Penny Stocks That Could Make Early Investors Rich
These are the penny stocks to buy, representing businesses with a promising growth outlook for the long term.
3 Penny Stocks to Turn $50,000 Into $1 Million: June 2024
These are undervalued penny stocks to buy as they represent companies with the likelihood of multi-fold growth in revenue.
Under-$10 Picks: 3 Biotech Stocks That Can Double Before the End of 2024
These are the biotech stocks under $10 that are attractively valued and have potential catalysts in the form of positive clinical trials news
Meme Mania Meets Medicine: 3 Biotech Stocks Primed to Soar
These are the biotech stocks to buy for a meme rally as they represent companies with positive impending news related to clinical trials.
The Next Novavax? 3 Biopharma Stocks to Buy Before They Boom
These are the biotech stocks to buy for a massive rally in the coming quarters on the back of positive clinical progress.
Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Treatment of Hypoparathyroidism at ENDO 2024
JERUSALEM, May 13, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered...
Entera Bio Reports Q1 2024 Financial Results and Provides Business Updates
JERUSALEM, May 10, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered...
Can You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024?
Discover three biotech stocks with explosive growth potential. Don't miss out on these great picks this year.
Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research
JERUSALEM, April 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered...
Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Months
JERUSALEM, March 26, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of orally delivered...
Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates
JERUSALEM, March 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered...
Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement
JERUSALEM, March 04, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered...
Entera Bio files to sell 16.5M ordinary shares for holders (NASDAQ:ENTX)
Learn about Entera Bio's recent filing of a prospectus for the offer and resale of up to 16,500,894 shares of its ordinary shares by selling shareholders.
Entera Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
JERUSALEM, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered...
Entera Bio And 3 Other Stocks Under $1 Insiders Are Buying
The Dow Jones index closed slightly higher on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Entera Bio Announces Closing of Private Placement - Extends Cash Runway into 2025
JERUSALEM, Dec. 26, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered...
Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera’s Next Generation Oral Peptide Platform
JERUSALEM, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered...
Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in Development
JERUSALEM, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”), a leader in the development of orally delivered...
Entera Bio Reports Key Milestone Relating to Oral PTH (1-34) Peptide (EB613) Phase 3 Program: ASBMR-SABRE Has Submitted to FDA the Full Qualification Plan to Approve BMD as a Surrogate Endpoint for Osteoporosis
JERUSALEM, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered...
Entera Bio Announces Collaboration with OPKO Biologics to Develop Oral Peptide Tablet Formulations for Obesity and Intestinal Malabsorption Syndromes
JERUSALEM, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX, “Entera”) and OPKO Biologics, Inc., a subsidiary of OPKO Health, Inc....
Bioventus And 3 Other Stocks Under $5 Insiders Are Buying
The Dow Jones closed lower by 175 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Entera Bio to Present Two Abstracts on its First-in-Class, Once Daily Oral hPTH(1-34) Peptide Tablets (EB613) for the Treatment of Post-Menopausal Women at High Risk of Fracture at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting
JERUSALEM, Aug. 16, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered...
Entera Bio Announces Q2 2023 Financial Results and Corporate Updates
JERUSALEM, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today reported corporate updates and financial results for the second quarter ended June 30, 2023.
Entera Bio Adds Sanofi Commercial Leader, Haya Taitel to its Board of Directors
JERUSALEM, June 07, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered...
Amgen, Entera end research collaboration (NASDAQ:ENTX)
Amgen (AMGN) and Israeli biopharma Entera Bio (ENTX) are ending a research collaboration that began in 2018. Read more here.